Challenges in access to oncology medicines: Policies and practices across the OECD and the EU

Suzannah Chapman, Valérie Paris and Ruth Lopert
Additional contact information
Suzannah Chapman: OECD
Valérie Paris: OECD
Ruth Lopert: OECD

No 123, OECD Health Working Papers from OECD Publishing

Abstract: With rapid advancements in oncology, even the wealthiest countries around the globe find it increasingly challenging to provide – and sustain – access to new medicines. Challenges include managing the uncertainty surrounding the extent of benefit of new treatments; complexities in determining the price and place in therapy of certain products; and the need to reconcile affordable, equitable access with spending efficiency and fiscal sustainability. Differences in timing of market entry and heterogeneity of coverage processes and policies contribute to inequity in access across the OECD and EU. Future policies and practices to promote sustainable access to oncology medicines will likely focus on improving affordability for patients and value-for-money for payers. An important element will be strengthening the evidence base, drawing on both clinical trial and “real world” evidence, and enhancing international collaboration and information sharing to improve countries’ collective capacity to address clinical and economic uncertainties.

JEL-codes: H51 I11 I13 I14 I18 L11 (search for similar items in EconPapers)
Date: 2020-11-13
References: Add references at CitEc
Citations: View citations in EconPapers (3)

Downloads: (external link)
https://doi.org/10.1787/4b2e9cb9-en (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:oec:elsaad:123-en

Access Statistics for this paper

More papers in OECD Health Working Papers from OECD Publishing Contact information at EDIRC.
Bibliographic data for series maintained by ().